ImmunityBio (IBRX) FCF Margin (2014 - 2026)
ImmunityBio (IBRX) posted quarterly FCF Margin of 172.94% for Q1 2026, up 34716.0% year-over-year from N/an in Q1 2025, and up 6.92% quarter-over-quarter from 185.8% in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) FCF Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported FCF Margin for 13 consecutive years, with 172.94% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 34716.0% year-over-year to 172.94%; the TTM figure through Mar 2026 stood at 210.53% (up 97455.0% YoY), while the FY2025 annual figure was 270.33%, up 239053.0% from the prior year.
- FCF Margin climbed to 172.94% in Q1 2026 per IBRX's latest filing, from 185.8% in the prior quarter.
- Across five years, FCF Margin topped out at 172.94% in Q1 2026 and bottomed at 534492.86% in Q1 2022.
- Historically, FCF Margin has averaged 107467.1% across 5 years, with a median of 28706.39% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 48792020 bps — and 2023, when it surged 50578647 bps.
- ImmunityBio's FCF Margin stood at 150216.44% in 2022, then surged by 51 bps to 73816.55% in 2023, then jumped by 99 bps to 1078.85% in 2024, then surged by 83 bps to 185.8% in 2025, then rose by 7 bps to 172.94% in 2026.
- Business Quant data shows IBRX's FCF Margin at 172.94% in Q1 2026, 185.8% in Q4 2025, and 209.66% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -22.35% |
| 10 | ImmunityBio | 8.48 Bn | 8.12 Bn | 50.94 Mn | -136.64% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -136.64% |
| Mar 31, 2026 | -174.58% |
| Dec 31, 2025 | -186.08% |
| Sep 30, 2025 | -217.37% |
| Jun 30, 2025 | -305.87% |
| Mar 31, 2025 | -526.89% |
| Dec 31, 2024 | -1,155.39% |
| Sep 30, 2024 | -1,646.66% |
| Jun 30, 2024 | -9,738.59% |
| Mar 31, 2024 | -270,902.50% |
| Dec 31, 2023 | -88,651.80% |
| Sep 30, 2023 | -113,509.76% |
| Jun 30, 2023 | -189,497.56% |
| Mar 31, 2023 | -28,706.39% |
| Dec 31, 2022 | -150,216.44% |
| Sep 30, 2022 | -81,809.32% |
| Jun 30, 2022 | -306,288.57% |
| Mar 31, 2022 | -730,550.00% |
| Dec 31, 2021 | -21,036.41% |
| Sep 30, 2021 | -122,345.45% |